People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.
DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).
The pilot MIDDAS study suggests that a 2-day per week very-low-calorie diet could be a viable alternative to a continuous diet for people with type 2 diabetes who struggle with this approach.
Levels of circulating C-peptide in people with type 1 diabetes reflect the numbers of remaining beta cells across different ages at diagnosis and durations of disease, confirm UK researchers.
People with type 2 diabetes, especially young people, do not receive treatment for hypertension and dyslipidemia in a timely manner, even when they have high cardiovascular risk, study results show.
The development of type 2 diabetes at a young age disproportionately affects people of South Asian and African–Caribbean ethnicity, and obesity is associated with early-onset diabetes in all ethnic groups, indicates research presented at the virtual 56th EASD Annual Meeting.
DAPA-CKD lead investigator Hiddo Heerspink discusses the positive outcomes of dapagliflozin treatment in people with kidney disease both with and without type 2 diabetes (8:13).
Lead investigator Milton Packer compares the EMPEROR-Reduced results with those of the DAPA-HF trial, and talks about how SGLT2 inhibitors will impact the treatment of heart failure (6:27).
DiRECT trial dietitian Alison Barnes discusses the challenges and triumphs of using a very-low-calorie, total-meal-replacement diet to help people with type 2 diabetes achieve weight loss and maintenance (25:34).
Is this increasingly popular weight management tactic an option for your patients with type 2 diabetes? Primary care physician Jay Shubrook and Jamie Katuna explain in this illustrative case study.
A small randomized crossover trial indicates that treatment with empagliflozin in people with type 2 diabetes and heart failure already using a loop diuretic results in increased urine output without sodium loss.
